• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Evolus Inc.

    11/6/24 5:22:20 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EOLS alert in real time by email
    S-8 1 evoluss-8november2024espp.htm S-8 Document

             As filed with the Securities and Exchange Commission on November 6, 2024

    Registration No. 333-


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ___________________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    ___________________
    Evolus, Inc.
    (Exact name of registrant as specified in its charter)
    ___________________
    Delaware46-1385614
    (State or other jurisdiction of incorporation or organization)
    (I.R.S. Employer Identification No.)

    520 Newport Center Drive, Suite 1200
    Newport Beach, California 92660
    (Address of Principal Executive Offices) (Zip Code)
    Evolus, Inc. 2024 Employee Stock Purchase Plan
    (Full title of the plans)
    ___________________
    David Moatazedi
    President and Chief Executive Officer
    Evolus, Inc.
    520 Newport Center Drive, Suite 1200
    Newport Beach, California 92660
    (949) 284-4555
    (Name and address of agent for service) (Telephone number, including area code, of agent for service)
    ___________________
    Copies to:
    Mark Peterson, Esq.
    O’Melveny & Myers LLP
    610 Newport Center Drive, Suite 1700
    Newport Beach, California 92660
     (949) 823-6900
    Jeffrey J. Plumer
    General Counsel
    Evolus, Inc.
    520 Newport Center Drive, Suite 1200
     Newport Beach, California 92660
    (949) 284-4555

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b–2 of the Exchange Act.
    Large accelerated filer☐Accelerated filer☒
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    PART I

    INFORMATION REQUIRED IN THE
    SECTION 10(a) PROSPECTUS

        The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).

    PART II

    INCORPORATION BY REFERENCE OF CONTENTS OF
    REGISTRATION STATEMENT ON FORM S-8

    Item 3.    Incorporation of Certain Documents by Reference
    The following documents of Evolus, Inc. (the "Company" or "Registrant") filed with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:
    (a)    The Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2023, filed with the Commission on March 7, 2024 (Commission File No. 001-38381);
    (b)     The Company's Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, filed with the Commission on May 7, 2024, July 31, 2024, and November 6, 2024, respectively (each, Commission File No. 001-38381);
    (c)    The Company’s Current Reports on Form 8-K filed with the Commission on March 13, 2024, April 3, 2024, June 11, 2024, and July 1, 2024 (each, Commission File No. 001-38381, and in each case only as to the information “filed” with the Commission thereunder for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and not as to information “furnished” thereunder); and
    (d)    The description of the Company’s Common Stock contained in its Registration Statement on Form 8-A filed with the Commission on February 1, 2018, as modified by the description of the Company’s Common Stock contained in Exhibit 4.3 to the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2023, filed with the Commission on March 7, 2024 (each, Commission File No. 001-38381), and any other amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.
    Item 4.        Description of Securities

    Not applicable.

    Item 5.    Interests of Named Experts and Counsel
    The validity of the issuance of securities registered hereby is passed on for the Company by Jeffrey J. Plumer. Mr. Plumer is General Counsel, of the Company and is compensated by the Company as an employee. Mr. Plumer holds 89,026 shares of Company common stock, 95,863 Company restricted stock units that are payable in an equivalent number of shares of Company common stock, up to 23,799 Company performance restricted stock units that are payable in various numbers of shares of Company common stock depending on achievement of certain performance milestones, and Company stock options to acquire up to an additional 379,883 shares of Company common stock.



    Item 6.        Indemnification of Directors and Officers.

    Section 145 of the General Corporation Law of the State of Delaware (“DGCL”) provides that a Delaware corporation may indemnify any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such corporation as an officer, director, employee or agent of another corporation or enterprise. Except in the case of an action by or in the right of the corporation (i.e., a derivative action), the indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. With respect to an action by or in the right of the corporation, the indemnity may only include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests except that no indemnification is permitted without judicial approval if such person is adjudged to be liable, unless the Delaware Court of Chancery, or the court in which such action or suit was brought, determines that despite the adjudication of liability, such person is fairly and reasonably entitled to indemnity for such expenses. Where a present or former officer or director is successful on the merits or otherwise in the defense of any action, suit or proceeding referred to above, the corporation must indemnify him or her against the expenses (including attorneys’ fees) by him or her in connection therewith. The Registrant’s amended and restated certificate of incorporation and amended and restated bylaws provide for the indemnification of the Registrant’s directors and officers to the fullest extent permitted under the DGCL.

    Section 102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any: (i) transaction from which the director derives an improper personal benefit; (ii) act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; (iii) willful or negligent violations of Delaware law governing the authorizations of dividends, stock repurchases, and redemptions, as provided in Section 174 of the DGCL; or (iv) breach of a director’s duty of loyalty to the corporation or its stockholders. The Registrant’s amended and restated certificate of incorporation includes such a provision. Expenses incurred by any of the Registrant’s officers or directors in defending any such action, suit or proceeding in advance of its final disposition shall be paid by the Registrant upon delivery to the Registrant of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the Registrant.

    The Registrant has entered into separate indemnification agreements with the Registrant’s directors and officers. These indemnification agreements may require the Registrant, among other things, to indemnify the Registrant’s directors and officers for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by such director or officer in any action or proceeding arising out of his or her service as one of the Registrant’s directors or officers, or as a director, officer, employee or agent of any of the Registrant’s subsidiaries or any other company or enterprise to which the person provides services at the Registrant’s request.

    The Registrant maintains a general liability insurance policy that covers certain liabilities of directors and officers of the Registrant arising out of claims based on acts or omissions in their capacities as directors or officers and the Registrant intends to maintain such insurance coverage.

    Item 7.        Exemption from Registration Claimed.

    Not applicable

    Item 8.    Exhibits.

    The following exhibits are filed herewith or incorporated by reference as part of this Registration Statement:



    Exhibit No.Description
    4.1
    Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on February 12, 2018).
    4.2
    Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated June 12, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on June 14, 2023
    4.3
    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on February 12, 2018).
    4.4
    Specimen certificate evidencing shares of common stock of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-222478)).
    5*
    Opinion of Counsel (Legality of Shares)
    23.1*
    Consent of independent registered public accounting firm.
    23.2*
    Consent of Counsel (included as part of Exhibit 5).
    24.1
    Power of Attorney (included on signature page hereto).
    99.1
    2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 11, 2024)
    107*
    Filing fee table

    *    Filed herewith





    Item 9.        Undertakings.

    (a)    The undersigned registrant hereby undertakes:

    (1)    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii)    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
    (iii)    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
    provided, however, that paragraphs (a)(1)(i) and(a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

    (2)    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b)    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c)    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.



    SIGNATURES
        Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newport Beach, State of California, on November 6, 2024.
    EVOLUS, INC.
    /s/ David Moatazedi
    By:David Moatazedi
    President and Chief Executive Officer
        KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Moatazedi and Sandra Beaver and each or either of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8, including any and all post-effective amendments and amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
        Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ David MoatazediPresident, Chief Executive Officer and
    Member of the Board of Directors
    (Principal Executive Officer)
    November 6, 2024
    David Moatazedi
    /s/ Sandra BeaverChief Financial Officer
    (Principal Financial and Accounting Officer)
    November 6, 2024
    Sandra Beaver
    /s/ Vikram MalikChairman of the Board of DirectorsNovember 6, 2024
    Vikram Malik
    /s/ Simone BlankDirectorNovember 6, 2024
    Simone Blank
    /s/ Albert White IIIDirectorNovember 6, 2024
    Albert White III
    /s/ David GillDirectorNovember 6, 2024
    David Gill



    /s/ Karah ParschauerDirectorNovember 6, 2024
    Karah Parschauer
    /s/ Brady StewartDirectorNovember 6, 2024
    Brady Stewart


    Get the next $EOLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EOLS

    DatePrice TargetRatingAnalyst
    8/6/2025Buy → Hold
    Needham
    4/17/2025$21.00Buy
    BTIG Research
    1/29/2024$10.00 → $16.00Equal Weight → Overweight
    Barclays
    6/23/2022$18.00Buy
    Needham
    5/12/2022$8.00 → $10.00Underweight → Equal Weight
    Barclays
    1/20/2022$11.00Hold → Buy
    Truist
    11/3/2021$22.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

    Provides 2026 Net Revenue Guidance and Maintains Projection for Full-Year 2026 Profitability1 Preliminary Unaudited Net Revenue of $88.6 Million to $90.6 Million for the Fourth Quarter 2025, Representing 12% to 15% Growth Over the Prior Year; Company Reaffirms an Important Milestone of Positive Non-GAAP Operating Income of $5 Million to $7 Million for Q4 2025 Preliminary Unaudited Net Revenue of $295.5 Million to $297.5 Million for the Full-Year 2025, Representing 11% to 12% Growth Over the Prior Year 2026 Net Revenue Guidance of $327.0 Million to $337.0 Million, Which Represents 11% to 13% Growth from Preliminary Unaudited 2025 Results; Company Remains on Track to Achieve Sustaina

    1/9/26 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase an aggregate of 17,871 shares of Evolus and an aggregate of 45,063 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan, with a grant and vesting commencement date of November 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Na

    11/14/25 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Reports Third Quarter 2025 Financial Results

    Total Net Revenue of $69.0 Million for Q3 2025, Up 13% from Q3 2024; Year-To-Date Growth of 10% Global Jeuveau® Net Revenue of $63.2 Million for Q3 2025, Up from $59.7 Million in Q2 2025, Reflecting Sequential Growth That Outperformed Typical Seasonal Trends Evolysse™ Delivered $5.7 Million in Revenue for Q3 2025 Marking the Strongest Hyaluronic Acid (HA) Filler Debut in Over a Decade Company Now Expects to Achieve Positive Non-GAAP Operating Income of $5 Million to $7 Million in Q4 2025; Remains on Track to Achieve Sustainable Annual Profitability1 Beginning in 2026 Reaffirms 2025 Net Revenue Guidance of $295 Million to $305 Million and Non-GAAP Operating Expenses of $208 Million

    11/5/25 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    SEC Filings

    View All

    Evolus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Evolus, Inc. (0001570562) (Filer)

    1/9/26 8:34:50 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.

    SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/25 4:43:42 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.

    SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/25 1:37:11 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Moatazedi David sold $75,361 worth of shares (10,539 units at $7.15), decreasing direct ownership by 3% to 354,388 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    12/29/25 6:42:08 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Avelar Rui sold $16,168 worth of shares (2,261 units at $7.15), decreasing direct ownership by 0.63% to 356,821 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    12/29/25 6:42:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Mitchell Tatjana was granted 104,603 shares (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    10/9/25 4:57:34 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stewart Brady bought $204,486 worth of shares (30,000 units at $6.82), increasing direct ownership by 51% to 88,629 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    8/18/25 4:28:22 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director White Albert G Iii bought $189,000 worth of shares (20,000 units at $9.45), increasing direct ownership by 66% to 50,378 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    6/10/25 5:04:47 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evolus downgraded by Needham

    Needham downgraded Evolus from Buy to Hold

    8/6/25 7:20:38 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Evolus with a new price target

    BTIG Research initiated coverage of Evolus with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus upgraded by Barclays with a new price target

    Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously

    1/29/24 7:09:38 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Leadership Updates

    Live Leadership Updates

    View All

    Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of strategic and operational finance leadership across both public and private companies in retail, consumer, data, and technology-driven businesses. She brings a proven track record of driving revenue growth, scaling organizations, and leading transformation efforts through disciplined financial management and strategic execution. Most recently, Ms. Mitchell served as Senior Vice President of Corporate Finance at Experian

    9/8/25 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Announces Appointment of Albert G. White III to Board of Directors

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

    7/1/24 8:00:00 AM ET
    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati

    1/4/24 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/24 4:50:28 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/24 4:00:06 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/13/24 5:38:05 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Financials

    Live finance-specific insights

    View All

    Evolus Reports Third Quarter 2025 Financial Results

    Total Net Revenue of $69.0 Million for Q3 2025, Up 13% from Q3 2024; Year-To-Date Growth of 10% Global Jeuveau® Net Revenue of $63.2 Million for Q3 2025, Up from $59.7 Million in Q2 2025, Reflecting Sequential Growth That Outperformed Typical Seasonal Trends Evolysse™ Delivered $5.7 Million in Revenue for Q3 2025 Marking the Strongest Hyaluronic Acid (HA) Filler Debut in Over a Decade Company Now Expects to Achieve Positive Non-GAAP Operating Income of $5 Million to $7 Million in Q4 2025; Remains on Track to Achieve Sustainable Annual Profitability1 Beginning in 2026 Reaffirms 2025 Net Revenue Guidance of $295 Million to $305 Million and Non-GAAP Operating Expenses of $208 Million

    11/5/25 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus to Report Third Quarter Financial Results on November 5, 2025

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephoni

    10/22/25 8:00:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Global Net Revenue of $69.4 Million for Q2 2025, Up 4% from Q2 2024 in a Market Where Overall U.S. Aesthetic Procedures Decreased; Growth Driven by the Successful Launch of Evolysse™ and Continued Strength in International Markets Evolysse™ Delivered $9.7 Million in Revenue for Q2 2025, Marking the Strongest Filler Launch Quarter in Over a Decade and Providing a Solid Foundation for Second Half Growth Expects to Achieve Meaningful Profitability1 in Q4 2025 and Annual Profitability1 Beginning in 2026; Strategic Cost Structure Optimization Expected to Yield At Least $25 Million in Non-GAAP Operating Expense Savings for 2025 Resets 2025 Net Revenue Guidance to $295 Million to $305 Mi

    8/5/25 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care